How many drugs treat Infectious disorder of joint?

Drug Landscape tracks 10 marketed treatments for Infectious disorder of joint (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Infectious disorder of joint?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/infectious-disorder-of-joint.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infectious disorder of joint — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infectious disorder of joint (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infectious disorder of joint, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
AZLOCILLIN	AZLOCILLIN	Bayer Pharmaceuticals Corp	azlocillin		1982-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Cephalotin	cefalotin	Eli Lilly	cefalotin	Solute carrier family 22 member 8	1974-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in Infectious disorder of joint
Bristol-Myers Squibb · 4 drugs in Infectious disorder of joint
GSK · 3 drugs in Infectious disorder of joint
Merck & Co. · 3 drugs in Infectious disorder of joint
Pai Holdings Pharm · 2 drugs in Infectious disorder of joint
Bayer AG · 1 drug in Infectious disorder of joint
Bayer Pharmaceuticals Corp · 1 drug in Infectious disorder of joint
Centre Hospitalier Universitaire Vaudois · 1 drug in Infectious disorder of joint
Eli Lilly · 1 drug in Infectious disorder of joint
Generic (originally Roche) · 1 drug in Infectious disorder of joint
Generic (originally Upjohn/Pfizer) · 1 drug in Infectious disorder of joint
HaEmek Medical Center, Israel · 1 drug in Infectious disorder of joint

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infectious disorder of joint:

Cite this brief

Drug Landscape (2026). Infectious disorder of joint — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infectious-disorder-of-joint. Accessed 2026-06-10.

Infectious disorder of joint full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing